Skip to content
Politically.com Search all
Menu

2026 · 3rd Quarter (July 1 - Sep 30)

AMGEN

Filed by THE MCMANUS GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-11-02 06:26:10 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 20, 2026
Income
$60,000.00
Expenses
Not reported
Client
AMGEN
Filing UUID
c6849bd8-8096-42cf-95a6-1b655ee61ae2
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

MMM · Medicare/Medicaid

Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement under Medicare Part B drugs, including H.R. 4299 -Protecting Patient Access to Cancer and Complex Therapies Act Policies related to the Most Favored Nation Drug Pricing Model

Literal federal measure citations: H.R. 4299

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.